At a glance
| Abbreviation | HCV1a, HCV1b, HCV2a, HCV2b |
|---|---|
| ICTV species | Orthohepacivirus hominis |
| Family | Hepaciviridae |
| Baltimore class | IV — (+)ssRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: hepatitis C virus genotype 1a; hepatitis C virus genotype 1b; hepatitis C virus genotype 2a; hepatitis C virus genotype 2b; hepatitis C virus genotype 3a; hepatitis C virus genotype 3k; hepatitis C virus genotype 4a; hepatitis C virus genotype 5a; hepatitis C virus genotype 6a; hepatitis C virus genotype 6g; hepatitis C virus genotype 7a; HCV and 8 more
Riboviria › Kitrinoviricota › Flasuviricetes › Amarillovirales › Hepaciviridae › Orthohepacivirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Kitrinoviricota |
| Class | Flasuviricetes |
| Order | Amarillovirales |
| Family | Hepaciviridae |
| Genus | Orthohepacivirus |
| ICTV identifier | ICTV19910774 |
| NCBI taxon | 3052230 |
| Exemplar isolate | AF009606 |
Host evidence
- human: 179,843 GenBank records
- horse: 28 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
Not searched yet. Burden, severity and transmissibility figures have not been curated for this virus yet. When they are, each will carry the exact sentence from its source.
Vaccines
Not searched yet. No vaccine for this virus appears in the vaccine pipeline dataset. That dataset tracks candidates and licensed products the site follows; it is not a complete register of every licensed vaccine, so this is not evidence that none exists.
Antivirals
| Name | Mechanism | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|
| Elbasvir And GrazoprevirZEPATIER | Protease inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]; SPL id 227ae348-5f6f-44d8-a6dc-103e63d28102 · verified 2026-10-30 |
| Glecaprevir And PibrentasvirMavyret | Protease inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]; SPL id c1aa97e0-7350-4286-ac17-915bcdf0b08a · verified 2026-10-30 |
| Ledipasvir And SofosbuvirLedipasvir and Sofosbuvir | NS5A inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE Ledipasvir and sofosbuvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ]: genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin Ledipasvir and sofosbuvir is a Hepatitis C Virus NS5A Inhibitor [EPC]; SPL id bd8387fe-8338-4241-b084-aec76726f8a9 · verified 2026-10-30 |
| Sofosbuvir, Velpatasvir, And VoxilaprevirVosevi | Protease inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]; SPL id 6ce7dd60-defa-4530-bff3-de03885e318a · verified 2026-10-30 |
| Velpatasvir And SofosbuvirEpclusa | NS5A inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Hepatitis C Virus NS5A Inhibitor [EPC]; SPL id 4e28b652-df20-450d-9f6e-4cc6e355e223 · verified 2026-10-30 |
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Other Hepaciviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose